Premium
Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin
Author(s) -
Kelly J. M.,
Belding B. A.,
Schaefer A. K.
Publication year - 2010
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2010.00208.x
Subject(s) - bleomycin , medicine , surgery , adverse effect , chemotherapy
Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone. This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA. Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10–20 U m −2 ). A seventh dog presented with advanced, nonresectable AA was treated palliatively. One to sixteen treatments were administered (median, 5). Six of the seven dogs had a complete response within 4 months from initial IL injection (median, 1.5 months), whereas the palliative case had approximately 25% decrease in tumour volume 14 days from initial injection. Local recurrence was not observed during the study period, with a median follow‐up time of 842 days. Adverse effects were limited to wound formation with bone exposure ( n = 4), mild tissue reactions ( n = 3), local swelling ( n = 2) and local infection ( n = 1). The conclusions of this study show IL bleomycin is an effective treatment for canines with AA.